News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Paladin Labs Inc. (CC:PLB) and Somaxon Pharmaceuticals, Inc. (SOMX) Announce Filing of New Drug Submission for Silenor┬«



2/23/2012 6:07:32 AM

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor® (doxepin) for the treatment and symptomatic relief of insomnia.

Read at BioSpace.com


comments powered by Disqus
   
Insomnia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES